Ascendis Pharma

Company snapshot

Ascendis Pharma Endocrinology is a pharma organization headquartered in EU. Primary therapeutic focus areas include Growth Hormone Deficiency, Pediatric. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (2).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Ascendis Pharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Ascendis Pharma.

1. Jun 8, 2026 Clinical update

   ASND0047 — Phase 3

2. Jun 8, 2026 Clinical update

   Once weekly subcutaneous injection of TransCon hGH — Phase 3

3. Sep 25, 2025 Patent grant

   Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin

4. Sep 10, 2020 Patent grant

   FORMES POSOLOGIQUES D'HORMONE DE CROISSANCE A ACTION PROLONGEE AYANT UNE EFFICACITE SUPERIEURE A UNE DOSE DE SOMATROPINE QUOTIDIENNE

5. Dec 14, 2017 Patent grant

   Novel Polymeric hGH Prodrugs

View all clinical trial activity →

• What is Ascendis Pharma?

  Ascendis Pharma Endocrinology is a pharma organization headquartered in EU. Primary therapeutic focus areas include Growth Hormone Deficiency, Pediatric. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Cli

• Is Ascendis Pharma publicly traded?

  Ascendis Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Ascendis Pharma develop or market?

  We link 7 drug profile(s) where Ascendis Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ascendis-pharma-endocrinology-division-a-s#company-drugs.

• What are the latest developments for Ascendis Pharma?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Ascendis Pharma focus on?

  Ascendis Pharma focuses on Growth Hormone Deficiency, Pediatric based on our analysis of their pipeline programs and drug development activities.